Published in PLOS One on 2026-09-22, this study is presented as an attributed evidence briefing. The excerpts below are the original researchers’ words, reproduced under their Creative Commons Attribution licence. Health Signal has selected the abstract and, where needed, opening background paragraphs; the complete methods, results, limitations and references remain in the linked paper.
Original authors: Joseph Mwaka, Conrad Sserunjogi, Jesca Natalayi, Felix Bongomin
Source: PLOS One • DOI 10.1371/journal.pone.0358066
Read the complete primary study ↗ · Creative Commons Attribution licence
From the researchers
Abstract
Sub-Saharan Africa carries a disproportionate burden of HIV-associated malignancies. The contemporary tumour spectrum in the dolutegravir (DTG) era remains incompletely characterised in East African routine HIV-care settings. The immunovirological context at the time of cancer or benign tumor diagnosis is similarly under-described. We sought to describe the spectrum, malignant fraction, and immunovirological correlates of neoplasms diagnosed at a specialised HIV centre in Kampala, Uganda.
We conducted a retrospective, cross-sectional analysis of 219 tumour records identified within the longitudinal clinical cohort of people living with HIV (PLHIV) in continuous care at Mildmay Hospital, contributed by 216 individual patients (three of whom each had two separate tumour diagnoses on different dates) between November 2017 and January 2026. Tumours were classified by ICD-10 disease group and malignancy status (benign/malignant). Bivariate associations with malignancy status were tested using χ² or Fisher exact tests for categorical variables and Mann–Whitney U tests for continuous variables (two-sided α = 0.05), with Benjamini–Hochberg false discovery rate (FDR) correction applied across each panel of comparisons given the number of variables tested. Crude odds ratios (OR) with 95% confidence intervals (CI) were computed for dichotomous comparisons. A sensitivity analysis restricted to one tumour record per patient (n = 216) was performed to assess the influence of the three patients with two records each.
The cohort had a median age of 47 years (IQR 39–54) and was 127/219 (58.0%) female. Overall, 138/219 tumours (63.0%) were malignant. Kaposi sarcoma (KS) was the most frequently registered malignancy (n = 65; 47.1% of all malignant tumours; 29.7% of the full cohort). Among 155 records with viral load data, 133 (85.8%) were virally suppressed at tumour diagnosis, yet 70/133 (52.6%) of those suppressed records were malignant. Advanced WHO clinical stage (III/IV) at ART initiation was associated with malignant diagnosis (OR 3.51, 95% CI 1.54–8.81; FDR-adjusted p = 0.003). Median CD4 at ART initiation was lower among malignant compared with benign tumour records (147 vs 476 cells/µL; FDR-adjusted p = 0.001), and median ART duration before diagnosis was shorter (37 vs 101 months; FDR-adjusted p < 0.001). Restricting the analysis to KS versus other malignancies only (n = 138), KS patients had lower CD4 at ART initiation (136 vs 171 cells/µL, p = 0.079) and markedly shorter ART duration before diagnosis (4 vs 63 months, p < 0.001) than patients with other malignancies. All associations were materially unchanged in the patient-level sensitivity analysis.
HIV-associated tumours in this Ugandan cohort remain predominantly malignant and are dominated by KS despite high viral suppression rates. Malignancy clusters among patients with low pre-ART CD4 counts, advanced WHO stage, and short ART duration, though these are unadjusted, hypothesis-generating comparisons rather than evidence of causal or temporal gradients. These data establish the analytic platform for a prospective HIV-oncology cohort at Mildmay Hospital and Mildmay Research Centre and inform context-appropriate cancer screening priorities.
Reading this evidence
Use the full paper to check the study design, participant selection, comparator and outcome definitions before drawing a practical conclusion. An association does not by itself show cause and effect. A reported performance measure needs its denominator and uncertainty. A finding from a particular facility, sample or time period should retain that scope when it is discussed elsewhere.
This briefing makes the source accessible within the wider research & evidence desk. It does not assess an individual patient or certify a product. When considering relevance to another health system, examine the original authors’ account of context and limitations, then seek local implementation evidence. The related reporting below provides other studies to read alongside this one; it is a topic connection, rather than a claim that their results are directly comparable.
© 2026 Joseph Mwaka, Conrad Sserunjogi, Jesca Natalayi, Felix Bongomin. Excerpts reproduced under CC BY. Selection, formatting and contextual notes by Health Signal. The researchers are the authors of the source study, not members of Health Signal’s staff.
Explore connected evidence
- Evidence brief: Inpatient mortality and associated clinical factors among people living with HIV with cryptococcal meningitis in Uganda: A retrospective cohort study
- Evidence brief: Prevalence and factors associated with treatment delay among colorectal cancer patients at Mulago National Referral Hospital and the Uganda Cancer Institute: A cross-sectional study
- Evidence brief: Empiric tuberculosis treatment and 12-month mortality among sputum GeneXpert-negative adults living with HIV in Uganda in the era of widespread antiretroviral therapy: A prospective cohort study
